Patients taking muscle relaxants at elevated risk of COPD exacerbation, unravels research
A new study published in the Chest Journal found that individuals using methocarbamol or cyclobenzaprine were more likely to experience exacerbations of their chronic obstructive pulmonary disease (COPD). In accordance with recent data, using gabapentinoids (pregabalin and gabapentin) may increase the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Therefore, Irakli Lemonjava and her colleagues set out to look into any possible links between exacerbations of COPD and regularly prescribed muscle relaxants like methocarbamol and cyclobenzaprine.
The patients over the age of 18 who were diagnosed with COPD after January 1, 2000 were included in the study. They were divided into two groups where Group A consisted of patients taking either methocarbamol or cyclobenzaprine, and Group B consisted of patients not taking either of these drugs. This study focused on COPD exacerbations that occurred 1, 3, and 5 years after the index event and were classified by the international classification of diseases code J44.1.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.